Lung cancer has the highest worldwide cancer mortality rate. Early non-small cell lung cancer accounts for 84 percent of cases, with curative surgical intervention being the standard treatment.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Radiation Therapy
October 12, 2023
June 15, 2023
A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part of the diagnosis and staging phase.
January 27, 2021
An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
November 21, 2020
A scholarly and sober narrative review on , as the authors state, a ' hot topic' that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
June 11, 2019
In this retrospective review of the effects of radiation dose to the heart on long-term outcomes, 748 patients with regionally advanced non–small cell lung cancer were studied. An increasing cardiac radiotherapy dose was associated with an increased risk of MACE and all-cause mortality.
March 4, 2019
The complete pathologic response rate in this study is revealed to be low, lower than expected after stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer: only 60%. The authors suggest a combined approach (SABR plus surgery), adopted in this experimental phase 2 trial, as a possible management scheme.
January 9, 2019
Cao and colleagues compared outcomes with stereotactic body radiation therapy (SBRT) to surgery for patients with non–small cell lung cancer using a meta-analysis of 23 studies.
December 6, 2018
Kevin Franks of the Leeds Cancer Centre in the UK discusses recent advances in radiotherapy technology for the treatment of lung cancer.
October 23, 2018
Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard maintenance therapy. Overall survival for the intervention group was 41.2 mos vs 17.0 mos in those getting maintenance therapy (p=0.017).
October 11, 2018
This analysis of the National Cancer Database included over 2000 eligible patients resected with N2 disease who did not receive induction therapy. The addition of radiotherapy to postoperative chemotherapy did not affect survival in either the unmatched or the matched groups.